SPEAKERS
Matteo Bassetti, MD, PhD
Policlinico San Martino University Hospital, Genoa, Italy
Matteo Bassetti is Head of the Infectious Diseases Clinic of the Policlinico San Martino University Hospital in Genoa and Full Professor of Infectious Diseases of the University of Genoa, Italy. Dr Bassetti studied at the University of Genoa School of Medicine and continued his medical education at the Yale University School of Medicine, New Haven, USA with an Infectious Diseases fellowship.
Dr Bassetti is president of the Italian Society of Anti-infective Therapy (SITA) and member of executive committee for the battle against antimicrobial resistance of the Italian Minister of Health (PNCAR). He is co-chair of the Intra-abdominal Infections Study Group of the International Society of Chemotherapy (ISC). He is member-elected (2018-2022) of International Council of the Immunocompromised Host Society (ICHS). From 2019 he is member of the council of International Sepsis Forum (ISF). He serves on the editorial board of several prestigious international journals. Author or co-author of 660 papers (H index 72; 21000 citations) published in International peer-review journals and several chapter’s book on antibiotic therapy, fungal infections, antimicrobial resistances, infections in immunocompromised patients and critically ill patients.
Andrew Davies, MD, PhD
University of Southampton, United Kingdom
BSc, BM, FRCP, PhD
Professor of Haematological Oncology
Consultant in Medical Oncology
Director Southampton Experimental Cancer Medicines Centre
Wessex Clinical Lead for Cancers in Teenagers and Young Adults
Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.
Prof. Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trials, including leading several first in man lymphoma studies.
He is the past Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults.
Sonata Jodelė, MD
Cincinnati Children's Hospital Medical Center, USA
Sonata Jodele, MD is a Research Professor in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s Hospital Medical Center, USA. Dr. Jodele’s clinical focus includes hematopoietic stem cell transplant and cell therapies for children and young adults. Her research interest centers on reducing organ toxicity after hematopoietic stem cell transplantation with a specific focus on hematopoietic stem cell transplant associated-thrombotic microangiopathy (TA-TMA). Dr.Jodele leads national and international committees, NIH and industry sponsored clinical studies investigating TA-TMA pathogenesis, TA-TMA screening, and early diagnostic tools, and studying novel therapeutic interventions for TA-TMA.
Ashish R. Kumar Md, PhD
Cincinnati Children’s Hospital Medical Center, USA
Prof. Ashish R. Kumar obtained his medical training (MBBS) from LTM Medical College in Mumbai, PhD in Anatomy and Cell Biology from the University of Iowa. Then obtained pediatric residency training at the Mayo Clinic in Rochester, Minnesota, and fellowship in Pediatric Hematology-Oncology from the University of Minnesota. In his clinical practice, he take care of children and young adults with immune-deficiencies and histiocytic diseases, including LCH and HLH. He is the co-director of our histiocytosis center, aimed at improving the outcome of patients with histiocytic diseases. His laboratory is engaged in research on infant leukemia and histiocytic neoplasms. He is also the director the clinical fellowship training program in pediatric hematology-oncology. As part of the faculty of the HLH-center of excellence, He is engaged in educating physicians across the world in diagnosing and treating patients with HLH.
Maria Victoria Mateos Manteca, MD, PhD
Hospital Clinico Universitario, Spain
Dr. María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department.
She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smouldering MM patients that have profoundly influenced current options for treating these patient populations.
She is also a member of the IMWG (International MM Working Group), IMS (International MM
Society), EHA and ASH. She has published over 200 papers in peer-reviewed international journals, some of which have become key references in the Multiple Myeloma field. She is Associate Editor of myeloma in Annals of Haematologysince 2011 and has acted as a reviewer for top journals such as NEJM, Lancetand Lancet Oncology. Among her invited presentations, she has recently contributed to the educational sessions of EHA 2012, ASH 2013, ASCO 2015, EHA 2016, ASCO and ASH 2017.
She has served on the EHA’s Scientific Program Committee and Advisory Board since 2013 until 2017, and on the ASH Scientific Committee on plasma cell diseases in 2015-2017. She is a Councillor on the EHA Board since 2015 for a four-year mandate, member of the Steering Committee for the Society of Hematologic Oncology (SOHO), member of the IMS board and member of the European School of Haematology (ESH) Scientific committee. She has published over 200 original papers in international journals. Her areas of interest include multiple myeloma, the biology of plasma cells and the news drugs development.
Sattva S Neelapu, MD
The University of Texas MD Anderson Cancer Center, USA
Dr. Sattva S Neelapu is a tenured Professor and Deputy Chair in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. After graduating from medical school at the Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India, he moved to the United States for Internal Medicine residency at the Coney Island Hospital in Brooklyn, New York, where he also served as a Chief Medical Resident. He completed his clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland. As a physician-scientist at MD Anderson, his research is focused on clinical and translational development of novel immunotherapies for B-cell malignancies. His work on the pivotal clinical trial of axicabtagene ciloleucel CD19 CAR T-cell therapy in aggressive B-cell lymphomas led to its FDA approval as the first CAR T therapy for lymphoma. Dr. Neelapu has authored or co-authored over 200 publications. He is nationally and internationally recognized for his expertise on CAR T-cell therapy in lymphomas and management of toxicities associated with CAR T-cell therapy.
Sue Pavord, MD
Oxford University Hospitals, United Kingdom
Dr Sue Pavord is a consultant hematologist at Oxford University Hospitals NHS Foundation Trust, Oxford, UK. She is also an associate senior lecturer in medicine at St Edmund Hall, University of Oxford, and a fellow of the Royal College of Pathologists and Royal College of Physicians. Her special areas of interest are immunohaematology, hemostasis, thrombosis and obstetric hematology.
Dr Pavord has been a key player in the identification of Vaccine-induced immune thrombosis and thrombocytopenia (VITT) as a new syndrome occurring after COVID-19 vaccination. She is chair of the Expert Haematology Panel focused on VITT, which has guided the UK’s prevention and management of this condition, through daily meetings held over 4 months during the surge of patients, analysis of the cases, communications with the UK regulatory authorities and development of guidelines with the National Institute for Health and Care Excellence. These actions have helped reduce morbidity and mortality of this devastating condition.
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center, USA
Farhad Ravandi, MD, is Janiece and Stephen A. Lasher Professor of Medicine and chief of the Section of Acute Myeloid Leukemia in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston. He graduated from the University of London, UK, and undertook residency and fellowship training at Baylor College of Medicine and MDACC. During this time, he specialized in the management of hematologic malignancies and stem cell transplantation. He then moved to the University of Illinois at Chicago as director of the leukemia program and interim director of stem cell transplant program for 3 years, until he joined the MDACC Department of Leukemia in 2003. He is board certified in internal medicine, hematology, and medical oncology.
Dr Ravandi’s main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias, including Philadelphia chromosome-positive acute lymphoblastic leukemia, hairy cell leukemia, and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematologic Oncology, and is a member of the editorial boards of several journals.